市場調査レポート
商品コード
1491690
自動微生物検出システム市場:構成要素、方法、最終用途別-世界予測2024-2030年Automated Microbial Detection System Market by Component (Consumables, Instruments, Software), Method (Genotypic Methods, Phenotypic Methods, Proteomics-based Methods), End-Use - Global Forecast 2024-2030 |
● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。 詳細はお問い合わせください。
自動微生物検出システム市場:構成要素、方法、最終用途別-世界予測2024-2030年 |
出版日: 2024年06月05日
発行: 360iResearch
ページ情報: 英文 188 Pages
納期: 即日から翌営業日
|
自動微生物検出システム市場規模は2023年に27億2,000万米ドルと推定され、2024年には30億1,000万米ドルに達し、CAGR 11.08%で2030年には56億8,000万米ドルに達すると予測されています。
自動微生物検出システム(AMDS)は、様々なサンプル中の微生物を最小限の手作業で同定・定量するために設計された高度な技術です。このシステムは、主に医薬品、飲食品、ヘルスケアなどの業界で、製品の安全性と規制基準の遵守を確保するために利用されています。微生物検出における高精度と信頼性の必要性、ヒューマンエラーの削減要求、ラボの効率性を高めるための処理時間の短縮化推進などの要因により、AMDSの用途は大きく拡大しています。これらのシステムは、感度の向上、大量のサンプルを迅速に処理する能力、汚染リスクの低減など、従来の微生物検出法よりも大きな利点を提供します。しかし、初期設定やメンテナンスにかかるコストが高いため、小規模な検査室にとっては大きな障壁となりうる。さらに、システムが複雑なため、オペレーターに専門的なトレーニングが必要となる場合もあり、即座の導入が制限される可能性もあります。とはいえ、バイオテクノロジーの進歩は続いており、複数の産業で安全性と品質が重視される傾向が強まっていることから、市場は上昇基調で成長すると予想されます。さらに、微生物検出のスピードと精度をさらに高める人工知能と機械学習アルゴリズムの統合は、市場成長の新たな道を開く。
主な市場の統計 | |
---|---|
基準年[2023] | 27億2,000万米ドル |
推定年[2024] | 30億1,000万米ドル |
予測年 [2030] | 56億8,000万米ドル |
CAGR(%) | 11.08% |
地域別の洞察
南北アメリカ、特に米国は、この地域の強固なヘルスケアインフラ、研究開発への多額の投資、医薬品、飲食品、ヘルスケアなどの業界全体で厳格な微生物検査を義務付ける厳しい規制により、AMDS導入の先陣を切った。米国食品医薬品局(FDA)による製品の安全性と品質管理に関する厳格なガイドラインは、高度なAMDSの需要に大きく貢献しています。欧州は、医薬品と食品安全に関する欧州連合(EU)の包括的な規制基準により、AMDS市場拡大の牙城となっています。ドイツ、英国、フランスなどの国々が最先端を走っており、先進的なヘルスケアシステムとバイオテクノロジー研究への多額の投資を活用しています。アジア太平洋地域は、急速な工業化、ヘルスケア分野の拡大、高品質な医薬品や食品に対する需要の高まりにより、AMDS市場で最も速い成長を示しています。中国やインドをはじめとする国々は、巨大な人口基盤、健康意識の高まりとともに増加する中間層、充実した医療インフラを背景に、極めて重要な位置を占めています。さらに、この地域の政府はヘルスケアや消費者製品に対してより厳しい規制を順次導入しており、効率的で正確な微生物検出システムの需要をさらに促進しています。
FPNVポジショニング・マトリックス
FPNVポジショニングマトリックスは、自動微生物検出システム市場におけるベンダーのポジショニングを評価する上で不可欠です。このマトリックスはベンダーの包括的な評価を提供し、事業戦略や製品満足度に関連する重要な指標を調査します。この詳細な評価により、ユーザーは自らの要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功のレベルを表す4つの象限、すなわちForefront(F)、Pathfinder(P)、Niche(N)、Vital(V)に分類されます。
市場シェア分析
市場シェア分析は、自動微生物検出システム市場におけるベンダーの現状について、洞察に満ちた詳細な評価を提供する包括的なツールです。ベンダーの貢献度を綿密に比較・分析することで、各ベンダーの業績や市場シェア争いの際に直面する課題について、より深い理解を得ることができます。これらの貢献には、全体的な収益、顧客ベース、その他の重要な指標が含まれます。さらに、この分析では、調査した基準年の期間に観察された蓄積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合性に関する貴重な考察を提供しています。このような詳細な情報を得ることで、ベンダーは市場競争において優位に立つために、より多くの情報に基づいた意思決定を行い、効果的な戦略を考案することができます。
戦略分析と推奨
戦略分析は、世界マーケットで確固たる足場を築こうとする組織にとって不可欠です。企業は、自動微生物検出システム市場における現在の地位を徹底的に評価することで、長期的な願望に沿った情報に基づいた意思決定を行うことができます。この重要な評価には、組織のリソース、能力、全体的なパフォーマンスを徹底的に分析し、中核となる強みと改善すべき領域を特定することが含まれます。
[188 Pages Report] The Automated Microbial Detection System Market size was estimated at USD 2.72 billion in 2023 and expected to reach USD 3.01 billion in 2024, at a CAGR 11.08% to reach USD 5.68 billion by 2030.
An automated microbial detection system (AMDS) is a sophisticated technology designed to identify and quantify microorganisms in various samples with minimal manual intervention. This system is primarily utilized in industries such as pharmaceuticals, food and beverage, and healthcare to ensure product safety and compliance with regulatory standards. Factors such as the need for high precision and reliability in microbial detection, the demand for reducing human error, and the push for faster processing times to increase laboratory efficiency have majorly increased the applications of AMDS. These systems offer significant advantages over traditional microbial detection methods, including enhanced sensitivity, the ability to process large volumes of samples quickly, and reduced risk of contamination. However, high initial setup and maintenance costs can be a significant barrier for smaller laboratories. Additionally, the complexity of some systems may require specialized training for operators, potentially limiting their immediate implementation. Nevertheless, ongoing advancements in biotechnology and a growing emphasis on safety and quality across multiple industries are expected to help the market grow on an upward trajectory. Moreover, the integration of artificial intelligence and machine learning algorithms to further enhance the speed and accuracy of microbial detection opens new avenues for market growth.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 2.72 billion |
Estimated Year [2024] | USD 3.01 billion |
Forecast Year [2030] | USD 5.68 billion |
CAGR (%) | 11.08% |
Regional Insights
The Americas, particularly the United States, spearheaded the adoption of AMDS due to the region's robust healthcare infrastructure, significant investment in research & development, and stringent regulations mandating rigorous microbial testing across industries such as pharmaceuticals, food & beverage, and healthcare. The U.S. Food & Drug Administration (FDA)'s strict guidelines for product safety and quality control significantly contribute to the demand for sophisticated AMDS. Europe stands as a stronghold for AMDS market expansion, driven by comprehensive regulatory standards by the European Union for pharmaceuticals and food safety. Countries including Germany, the UK, and France are at the forefront, leveraging advanced healthcare systems and substantial investment in biotechnology research. The Asia Pacific region showcases the fastest growth in the AMDS market, attributed to rapid industrialization, expanding healthcare sectors, and escalating demand for high-quality pharmaceuticals and food products. Countries including China and India are pivotal, driven by massive population bases, growing middle-class populations with increased health consciousness, and enhanced healthcare infrastructure. Moreover, governments in this region are progressively implementing stricter regulations for healthcare and consumer products, further fueling the demand for efficient and accurate microbial detection systems.
Market Insights
The market dynamics represent an ever-changing landscape of the Automated Microbial Detection System Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
FPNV Positioning Matrix
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Automated Microbial Detection System Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Automated Microbial Detection System Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Recent Developments
Strategic Partnership Between bioMerieux and FDA Aims to Enhance Food Safety through Innovative Pathogen Detection
bioMerieux has formed a strategic research partnership with the US Food and Drug Administration's (FDA) Center for Food Safety and Applied Nutrition, focusing on pioneering advances in food-borne pathogen detection. This collaboration underscores a unified effort to address critical public health issues by deploying advanced diagnostic tools against dangerous pathogens such as Shiga-toxin-producing E. coli, Cyclospora Cayetanensis, Salmonella spp., and Listeria monocytogenes. This partnership marks a proactive step towards mitigating health risks associated with contaminated foods, reflecting both entities' dedication to public health and safety through innovative research and technological development. [Published On: 2024-02-28]
Ancera Unveils Cutting-Edge Microbial Detection Tools
Ancera has launched microbial detection tools aimed at transforming the poultry industry by enhancing productivity, food safety, and intervention efficacy through rapid identification and enumeration of Clostridium perfringens and total viable bacteria (TVB). These tools, incorporated into Ancera's PIPER platform, represent a significant leap in addressing the dual challenges of maintaining animal welfare and ensuring food safety within poultry operations. The Clostridium perfringens assay is poised to offer unprecedented management of necrotic enteritis (NE) risk by allowing precise monitoring of the Clostridium load, thereby aiding in the assessment of intervention effectiveness and overall animal health. [Published On: 2024-01-22]
Collaborative Venture Between LBT and AstraZeneca Revolutionizing Sterility Monitoring in Drug Manufacturing
LBTnhas joined forces with AstraZeneca to spearhead the development of an advanced AI-driven analysis module, known as APAS Pharma, designed for the APAS Independence instrument. This innovative module aims to automate the detection of microbial growth on settle plates, a critical component in the sterility monitoring process during drug manufacturing. The development of APAS Pharma marks a significant leap forward from traditional manual methods of analyzing settle plates, which are prone to subjectivity and human error, towards a more reliable, automated system. [Published On: 2023-01-24]
Strategy Analysis & Recommendation
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Automated Microbial Detection System Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
Key Company Profiles
The report delves into recent significant developments in the Automated Microbial Detection System Market, highlighting leading vendors and their innovative profiles. These include Agilent Technologies, Inc., Becton, Dickinson and Company, Bio-ConTech, Bio-Rad Laboratories, Inc., BioMerieux S.A., Bruker Corporation, Charles River Laboratories, Danaher Corporation, Eppendorf AG, F. Hoffmann-La Roche Ltd., IDEXX Laboratories, Illumina, Inc., Lonza Group AG, Luminex Corporation, Merck KGaA, Neogen Corporation, Nova Biomedical, Pall Corporation, PerkinElmer Inc., Qiagen N.V., Rapid Micro Biosystems Inc., Sartorius AG, Shimadzu Corporation, Sysmex Corporation, and Thermo Fisher Scientific Inc..
Market Segmentation & Coverage